Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

MEDIMMUNE LIMITED

Home Clinical Trial Sponsors and OrganizationsMEDIMMUNE LIMITED

MEDIMMUNE LIMITED

1 FRANCIS CRICK AVENUE, Cambridge, United Kingdom

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

15

15 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

6

40.0%

Trial Status Distribution

Active, not recruiting

15

100.0%

Clinical Trials

Trials sponsored by this organization (15)

A Phase 2B study of multiple doses to evaluate the safety and treatment benefits of MEDI2070 in subjects with Crohn's Disease who have failed or are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy

Active, not recruiting

Jan 2016342 participants

Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults with Atopic Dermatitis

Active, not recruiting

Apr 2015184 participants

An exploratory clinical study to investigate mavrilimumab, an antibody being developed for the treatment of moderate to severe rheumatoid arthritis, an inflammatory condition that affects the joints versus a different antibody whose mechanism works by inhibiting tumor necrosis factor.

Active, not recruiting

Mar 2013138 participants

A Phase 2 study to test how effective MEDI8968 is in treating subjects with chronic bronchitis, emphysema, or both, in which airflow to the lungs is restricted.

Active, not recruiting

Feb 2012300 participants

A Phase 2 study to test how effective MEDI8968 is in treating subjects with chronic bronchitis, emphysema, or both, in which airflow to the lungs is restricted.

Active, not recruiting

Dec 2011300 participants

A Phase 2 study to test how effective MEDI8968 is in treating subjects with chronic bronchitis, emphysema, or both, in which airflow to the lungs is restricted.

Active, not recruiting

Dec 2011300 participants

A Phase 2 study to test how effective MEDI8968 is in treating subjects with chronic bronchitis, emphysema, or both, in which airflow to the lungs is restricted.

Active, not recruiting

Nov 2011300 participants

A Phase 2 study to test how effective MEDI8968 is in treating subjects with chronic bronchitis, emphysema, or both, in which airflow to the lungs is restricted.

Active, not recruiting

Nov 2011300 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials15
Approvals
News

Back to Organizations